download PDF - Newron

More documents

Recommendations

Info

who resigns or otherwise becomes unable to perform his duties. At least one member of the Board of Statutory Auditors and one alternate member must be registered with the national register of auditors (Registro dei Revisori Contabili). The other members, if not registered with the national register of auditors, must be registered in specific professional registers or must be chosen among certain university professors. All members of the Company’s Board of Statutory Auditors are registered with the national register of auditors. The Company’s Board of Statutory Auditors is responsible for reviewing the Company’s affairs and financial reporting and condition. It is required to review the Company’s activities in order to determine compliance with the by-laws and applicable Italian law, as well as report specific matters to the shareholders and to the court. The Board of Statutory Auditors, among other things, ensures (i) that the Company be managed in a sound manner and (ii) that the Company’s internal auditing, accounting and administrative procedures be adequate. The review of the Company’s books and records performed by its Board of Statutory Auditors does not constitute an audit in accordance with Italian auditing standards. Members of the Company’s Board of Statutory Auditors must receive notice of, and are required to attend, meetings of the Board, shareholders’ meetings and meetings of any executive committee of the Board. The following table sets forth certain information about the current members of the Company’s Board of Statutory Auditors, who have been appointed by the shareholders’ meeting of April 2, 2010. Name Position Member since Richard P. Murphy Chairman of the Board of Statutory Auditors Giorgio R. Fumagalli Permanent auditor 2007 Lucio G. Ricci Permanent auditor 2002 Luca G. Caretta Alternate auditor 2007 Chiara Peja Alternate auditor 2010 2002 Each of the members of the Company’s Board of Statutory Auditors also serves as statutory auditors for several other Italian and pharmaceutical companies. 26 Newron Annual Report 2011
Senior Management Members of the senior management Name Luca Benatti Ravi Anand Stefan Weber Marco Caremi Position at the Company Chief Executive Officer, Managing Director Chief Medical Officer Chief Financial Officer Vice-President Strategic Marketing and Head of Legal Affairs For a biography of Luca Benatti, Newron’s CEO, see “Board of Directors” above. None of the members of the senior management is a member of governing and supervisory bodies of important Swiss or foreign organizations, institutions and foundations outside of Newron. None of the members of the senior management holds permanent management or consultancy functions for important Swiss or foreign interest groups, and none of them has official functions or holds political posts besides those mentioned. None of them has previously covered functions for Newron or one of Newron’s subsidiaries besides those mentioned below. Ravi Anand, a Swiss resident, has been the Company’s Chief Medical Officer since May 2005. He received his university education in New Delhi, India, and his medical training in the specialties of psychiatry and neurology in the United States. For over 20 years, Dr. Anand has worked in international drug development and registration departments of major pharmaceutical companies, including F. Hoffmann-La Roche (Switzerland), Sandoz/Novartis (United States) and Organon (Netherlands). From 1993 to 1997, he was the Medical Director of CNS, Clinical Research at Sandoz Research Institute. From 1997 to 2001, he served as the international Head of CNS Medical Affairs at Novartis. From 2001 to 2003, he served as the global Head of CNS Clinical Research at Organon. Since 2003, Dr. Anand has been acting as a consultant for Newron and other clients. During his tenure in the pharmaceutical industry, Dr. Anand has worked in all phases (I through III) of drug development as well as in medical commercialization (phase IV). Overall, he has been responsible for the conduct of clinical trials in over 30 countries. He has been involved in over 30 investigational new drug applications, and over 7 international new drug applications. He has published extensively, including over 50 papers and 200 abstracts, posters and presentations. Senior Management – Newron Annual Report 2011 2 7
Page 1 and 2: Annual Report 2011
Page 3: Key Corporate Events Completion of
Page 6 and 7: Shareholders’ Letter Rolf Stahel
Page 8 and 9: Drug Portfolio Safinamide Adjunctiv
Page 10 and 11: Information for Investors Stock exc
Page 13 and 14: Corporate Governance
Page 15 and 16: Group Structure and Shareholders Ne
Page 17 and 18: To the best of Newron’s knowledge
Page 19 and 20: ight by the Company’s current sha
Page 21 and 22: Stock-based remuneration (stock opt
Page 23 and 24: Rolf Stahel has been the Chairman o
Page 25 and 26: Responsibilities and organization P
Page 27: Subcommittees The Board has formed
Page 31 and 32: Compensation, Shareholdings and Loa
Page 33 and 34: The total gross compensation and th
Page 35 and 36: Attendance and voting rights To att
Page 37 and 38: Auditors Upon proposal by the manag
Page 39: Information Policy Newron undertake
Page 42 and 43: Consolidated Statement of Income (I
Page 44 and 45: Consolidated Statement of Changes i
Page 46 and 47: Notes to the Consolidated Financial
Page 48 and 49: The following new standards, amendm
Page 50 and 51: (‘the functional currency’). Th
Page 52 and 53: P Share capital Ordinary shares and
Page 54 and 55: The Group did not enter into foreig
Page 56 and 57: sell of the property, plant and equ
Page 58 and 59: Other expenses increased by EUR 1,4
Page 60 and 61: 14 Intangible assets (In thousand e
Page 62 and 63: Government grants receivable includ
Page 64 and 65: A summary of the granted options is
Page 66 and 67: Amounts recognized under staff cost
Page 68 and 69: 29 Financial instruments by categor
Page 70 and 71: Auditors’ Report 68 Newron Annual
Page 72 and 73: Glossary Activities of Daily Living
Page 74 and 75: In vitro A biological or chemical p
Page 76 and 77: Product Candidate (or Clinical Comp
Page 78:
Imprint Publisher Newron Pharmaceut
show all

download PDF - Newron

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?